Korro Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Korro Bio, Inc. (KRRO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 426.06 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 112.26K shares, a 34.41% decline year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 313.80K shares, a 37.13% decline year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 19.40K shares, a 48.54% decline year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 62.40K shares, a 31.68% decline year-over-year.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 752.07K shares, a 198.67% increase from fiscal 2024.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 251.81K shares, a 69.87% decline from fiscal 2023.
- Korro Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 835.84K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 112.26K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 426.06K shares 10-Q · filed 2026-08-06 | 445.46K shares derived: sum of 3 quarters · filed 2026-08-06 | 507.86K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 313.80K shares 10-Q · filed 2026-05-07 | 333.20K shares derived: sum of 2 quarters · filed 2026-05-07 | 395.60K shares derived: sum of 3 quarters · filed 2026-05-07 | 566.76K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 19.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 81.80K shares derived: sum of 2 quarters · filed 2026-03-12 | 252.96K shares derived: sum of 3 quarters · filed 2026-03-12 | 752.07K shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 62.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 233.56K shares derived: sum of 2 quarters · filed 2025-11-12 | 732.66K shares 10-Q · filed 2025-11-12 | 770.37K shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 171.16K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 670.26K shares 10-Q · filed 2025-08-12 | 707.97K shares derived: sum of 3 quarters · filed 2025-08-12 | 799.31K shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 499.11K shares 10-Q · filed 2025-05-07 | 536.80K shares derived: sum of 2 quarters · filed 2025-05-07 | 628.15K shares derived: sum of 3 quarters · filed 2025-05-07 | 725.99K shares derived: sum of 4 quarters · filed 2025-05-07 |
| 2024-12-31 | 37.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 129.04K shares derived: sum of 2 quarters · filed 2025-03-18 | 226.88K shares derived: sum of 3 quarters · filed 2025-03-18 | 251.81K shares 10-K · filed 2025-03-18 |
| 2024-09-30 | 91.34K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 189.18K shares derived: sum of 2 quarters · filed 2024-11-12 | 214.11K shares 10-Q · filed 2024-11-12 | |
| 2024-06-30 | 97.84K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 122.77K shares 10-Q · filed 2024-08-13 | ||
| 2024-03-31 | 24.93K shares 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | 835.84K shares 10-K · filed 2024-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |